Reporting missing participant data in randomised trials: systematic survey of the methodological literature and a proposed guide

Objectives We conducted a systematic survey of the methodological literature to identify recommended approaches for how and what randomised clinical trial (RCT) authors should report on missing participant data and, on the basis of these approaches, to propose guidance for RCT authors. Methods We defined missing participant data (MPD) as missing outcome data for trial participants. We considered both categorical and continuous outcome data. We searched MEDLINE and the Cochrane Methodology Register for articles in which authors proposed approaches to reporting MPD from RCTs. We selected eligible articles independently and in duplicate and extracted data in duplicate. Using an iterative process of discussion and revisions, we used the findings to develop guidance. Results Of 10 501 unique citations identified, 13 articles reporting on 10 approaches proved eligible. The identified approaches recommend reporting the following aspects (from most to least frequently recommended): number of participants with MPD (n=10), reasons for MPD (n=7), methods used to handle MPD in the analysis (n=4), flow of participants (n=3), pattern of missingness (eg, whether at random) (n=3), differences in rates of MPD between trial arms (n=2), differences between participants with and without MPD (n=2), results of any sensitivity analyses (n=2), implication of MPD on interpreting the results (n=2) and methods used to prevent missing data (n=1). We propose a guide with nine items related to reporting the number, reasons, patterns, analytical methods and interpretation of MPD. Conclusions Most identified approaches invite trial authors to report the extent of MPD and the underlying reasons. Fewer approaches focus on reporting missingness patterns, methods for handling MPD and implications of MPD on results. Our proposed guidance could help RCT authors to better report, and readers to better identify participants with missing data.

[1]  G. Piaggio,et al.  Consort 2010 statement: extension to cluster randomised trials , 2012, BMJ : British Medical Journal.

[2]  R. Little,et al.  The design and conduct of clinical trials to limit missing data , 2012, Statistics in medicine.

[3]  Thomas Agoritsas,et al.  Handling trial participants with missing outcome data when conducting a meta-analysis: a systematic survey of proposed approaches , 2015, Systematic Reviews.

[4]  M. Kenward,et al.  Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls , 2009, BMJ : British Medical Journal.

[5]  Gordon H Guyatt,et al.  Addressing continuous data measured with different instruments for participants excluded from trial analysis: a guide for systematic reviewers. , 2014, Journal of clinical epidemiology.

[6]  J. Ioannidis,et al.  Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement , 2004, Annals of Internal Medicine.

[7]  D. Patrick Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  D. Polit,et al.  Intention-to-treat in randomized controlled trials: recommendations for a total trial strategy. , 2010, Research in nursing & health.

[9]  J. Harman,et al.  Attrition and related trends in scientific rigor: A score card for ART adherence intervention research and recommendations for future directions , 2008, Current HIV/AIDS reports.

[10]  D. Moher,et al.  CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials , 2010, Journal of pharmacology & pharmacotherapeutics.

[11]  G. Antes,et al.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials , 2011 .

[12]  J Zhang,et al.  Review of guidelines and literature for handling missing data in longitudinal clinical trials with a case study , 2006, Pharmaceutical statistics.

[13]  D. Osoba,et al.  Missing quality of life data in cancer clinical trials: serious problems and challenges. , 1998, Statistics in medicine.

[14]  David Moher,et al.  SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials , 2013, BMJ.

[15]  Yvonne Sylvestre CONSORT: missing missing data guidelines, the effects on HTA monograph reporting , 2011, Trials.

[16]  Matthias Briel,et al.  Inconsistent Definitions for Intention-To-Treat in Relation to Missing Outcome Data: Systematic Review of the Methods Literature , 2012, PloS one.

[17]  D. Osoba,et al.  Guidelines for reporting results of quality of life assessments in clinical trials , 1996, Quality of Life Research.

[18]  David Moher,et al.  Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. , 2013, JAMA.

[19]  N. Black CONSORT , 1996, The Lancet.

[20]  R T O'Neill,et al.  The Prevention and Treatment of Missing Data in Clinical Trials: An FDA Perspective on the Importance of Dealing With It , 2012, Clinical pharmacology and therapeutics.

[21]  Matthias Briel,et al.  Addressing Dichotomous Data for Participants Excluded from Trial Analysis: A Guide for Systematic Reviewers , 2013, PloS one.

[22]  R. Little,et al.  The prevention and treatment of missing data in clinical trials. , 2012, The New England journal of medicine.

[23]  J. Farrar,et al.  Reporting of missing data and methods used to accommodate them in recent analgesic clinical trials: ACTTION systematic review and recommendations , 2014, PAIN®.

[24]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[25]  V. Montori,et al.  An efficient strategy allowed English-speaking reviewers to identify foreign-language articles eligible for a systematic review. , 2014, Journal of clinical epidemiology.

[26]  Xin Sun,et al.  Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers. , 2013, Journal of clinical epidemiology.

[27]  Gordon H Guyatt,et al.  Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review , 2012, BMJ : British Medical Journal.

[28]  A. Troxel,et al.  Statistical analysis of quality of life with missing data in cancer clinical trials. , 1998, Statistics in medicine.